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These outstanding results have prompted investigators to address four major questions regarding the use of retinoids in this subgroup of leukemia. The first is: in whom do we prevent relapse with maintenance therapy? The second is: can exposure to chemotherapy be minimized? The third is: what are the important prognostic factors to tailor our therapy even better? And the fourth is: what is the best way to minimize toxicity associated with ATRA, specifically retinoid acid syndrome.
The PETHEMA Spanish cooperative group has addressed two of these areas and focused on administering maintenance chemotherapy to all patients and minimizing chemotherapy. In their trial, cytarabine is omitted both during induction and in consolidation, and maintenance ATRA, 6-MP, and methotrexate are administered to all patients. With that strategy, the 4-year disease-free survival rate of 167 patients who achieved complete remission out of 186 patients on the trial is 90%. The event-free survival for all 186 patients entered is 79%. 5 The PETHEMA group, along with the GIMEMA group, have looked at a combined cohort of patients treated with this approach and have identified prognostic factors. 3 White blood cell count at presentation and platelet count were important prognostic factors with which one could segregate patients into low risk, high risk, and intermediate risk. Low-risk patients had white counts less than 10 000 × 10 6 /l and a platelet count above 40 000 × 10 6 /l; high-risk patients had white blood cell counts above 10 000 × 10 6 /l; and intermediate-risk patients had white blood cell counts less than 10 000 × 10 6 /l and low platelet counts.
The most significant toxicity associated with ATRA induction therapy in APL is retinoic acid syndrome. This syndrome is a cardiorespiratory distress syndrome, similar in some ways to adult respiratory distress syndrome. In 167 patients treated on the North American Intergroup Trial, the most common symptoms were dyspnea, fever, pulmonary edema, pulmonary infiltrates requiring mechanical ventilation in about 25% of patients, pleural and pericardial effusions, episodic hypotension, and acute renal failure necessitating hemodialysis in sev- eral patients. 1, 6 Of the 167 patients, 44 developed retinoic acid syndrome and two died as a result. Autopsies showed an interstitial infiltrate of maturing myeloid cells in the lungs of patients with relative patency of the alveoli. This picture is not consistent with the leukostasis observed in patients with hyperleukocytosis particularly associated with monocytic or myelomonocytic differentiation. However, there were patients who progressed to develop intra-alveolar infiltrates.
The pathogenesis of retinoic acid syndrome has not been completely elucidated, but several pathophysiologic mechanisms have been proposed. There is evidence that cathepsin G, a serine protease which is known to enhance capillary permeability, is stimulated in patients treated with ATRA. 7 ATRA also causes increased expression of LFA-1 and other cellular adhesion molecules on the surface of the APL cell resulting in increased binding to adhesion molecules on epithelium. 8, 9 Hematopoietic growth factors, such as interleukin-1-␤, TNF-␣, and interleukin-6, which are known to promote leukocyte activation, may play a role in the clinical features of hypotension and pulmonary infiltrates. 10 We attempted to identify clinical factors associated with the development of retinoic acid syndrome in the US Intergroup Study of 44 patients. 6 There was an inverse association between the microgranular variant of APL and retinoic acid syndrome, but otherwise there were no other factors that were predictive. Other trials suggested that white blood cell count at presentation, peak white blood cell count, or the rate of rise of the white blood cell may be predictive, but in fact most studies have now shown that it is very difficult to identify factors that are predictive of who will develop this syndrome. In our analysis, we were unable to identify white blood cell count as a prognostic factor and, further, there was no difference in clinical outcome among patients who developed the syndrome and those who did not. This is in contrast to a study by the European APL group who found that the event-free survival and overall survival was different among patients who developed the syndrome compared to those who did not, even though there was no difference in complete remission rates among patients who developed the syndrome and those who did not. 11 Although it has been very difficult to identify factors that predict for retinoic acid syndrome, the question of the syndrome predicting for other complications, such as extramedullary relapse, has been addressed. Extramedullary relapse in patients with APL treated with chemotherapy historically has been a very rare observation. However, since the era of ATRA, there have been increasing reports of patients relapsing after prior therapy with ATRA in extramedullary sites, primarily in the central nervous system and skin, but other sites as well. 12, 13 This is certainly plausible given the fact that we know there is modulation of adhesion molecules with ATRA. If one presumes that retinoic acid syndrome is a syndrome of tissue infiltration by maturing myeloid cells, one can under-stand how perhaps certain sanctuary sites may be capable of withstanding the antileukemic effect of consolidation chemotherapy. In a study by Ko et al 14 there was a suggestion that patients who had ATRA did have a higher incidence of extramedullary relapse; in fact, among the patients with extramedullary disease, all had retinoic acid syndrome. These results suggest that there may be an association and are worthy of further investigation in a larger cohort of patients.
In earlier experiences before early recognition, 30% of patients with retinoic acid syndrome died as a result. 15 In the intergroup study in which ATRA was administered alone before chemotherapy, the incidence of the syndrome was 26% and with early recognition mortality was reduced to 5% with dexamethasone pretreatment. 1, 6 In another series in which ATRA was combined with chemotherapy either from the outset in every patient or with a provision of introducing chemotherapy early for the development of leukocytosis, 2, 11 there was a suggestion that the incidence of the syndrome may be reduced with concomitant chemotherapy and ATRA, although there appears to be no reduction in the mortality rate. In yet another study of ATRA given with prophylactic steroids alone (n = 72) or with chemotherapy for leukostasis (n = 15) by the Australian Leukemia Study Group, there was no real suggestion that the incidence or the mortality rate from retinoic acid syndrome was decreased. 16 Beginning in 1996, the GIMEMA investigators initiated prophylactic steroid treatment in patients receiving ATRA with prednisone, 30 mg daily, until complete remission and for the duration of ATRA therapy. This decreased the incidence of retinoic acid syndrome from 9 to 4%, all in patients who received ATRA plus chemotherapy and prophylactic steroids (Avvisati G, personal communication). One issue of controversy that has arisen with this approach is the potential for steroid-associated toxicity in the 90% of patients who likely do not need steroids, especially potentially problematic in the setting of a thrombocytopenic patient with acute leukemia.
While retinoic acid syndrome is decreasing in incidence, it remains a clinical problem. There is evidence that concurrent chemotherapy with or without prophylactic steroids may decrease the incidence of the syndrome. There are not any reliable predictive factors, however, that can reliably identify who should receive prophylactic steroids. The influence that retinoic acid syndrome may have on treatment outcome is not completely clear, although there is a suggestion that it may be inferior. There has been no report, interestingly, of the development of the syndrome in patients receiving maintenance therapy, which has become routine. The question should at least be raised as to whether prophylactic corticosteroid treatment is hazardous, particularly in this setting, and whether there should be a randomized trial to address the effects of steroids on outcome.
